Adlon Therapeutics L.P. Announces Two New Publications of Adhansia XR^® (methylphenidate HCl) Extended-Release Capsules CII Data

Adlon Therapeutics L.P. Announces Publication of Adhansia XR® (methylphenidate HCl) Extended-Release Capsules CII Study Data in the Journal of Attention Disorders

Adlon Therapeutics Secures Adhansia XR™ (methylphenidate HCI) Extended Release Capsules CII Formulary Coverage from Express Scripts

Adlon Therapeutics L.P. and Purdue Pharma L.P. Will Present Data from Adhansia XR™ (methylphenidate HCl) Studies Examining Sleep Quality Outcomes, Functional Outcomes and Executive Functioning at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting

Adlon Therapeutics L.P. and Purdue Pharma L.P. to Present Six Scientific Posters at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting

Adhansia XR™ (methylphenidate HCl) Extended Release Capsules CII, New ADHD Treatment from Adlon Therapeutics L.P., Now Available Throughout the U.S.

Adlon Therapeutics L.P. Announces FDA Approval for Adhansia XR™ (Methylphenidate HCL) Extended-release Capsules CII for the Treatment of ADHD